Your browser is no longer supported. Please, upgrade your browser.
Settings
EDSA Edesa Biotech, Inc. daily Stock Chart
EDSA [NASD]
Edesa Biotech, Inc.
Index- P/E- EPS (ttm)-0.72 Insider Own6.30% Shs Outstand8.74M Perf Week1.26%
Market Cap29.59M Forward P/E- EPS next Y-0.49 Insider Trans39.49% Shs Float4.72M Perf Month26.76%
Income-4.80M PEG- EPS next Q-0.23 Inst Own24.50% Short Float0.47% Perf Quarter6.27%
Sales0.60M P/S49.32 EPS this Y94.80% Inst Trans5.14% Short Ratio0.35 Perf Half Y-32.21%
Book/sh0.79 P/B4.08 EPS next Y35.10% ROA-75.30% Target Price- Perf Year-52.08%
Cash/sh- P/C- EPS next 5Y- ROE-85.40% 52W Range1.58 - 13.56 Perf YTD-21.46%
Dividend- P/FCF- EPS past 5Y58.90% ROI- 52W High-76.25% Beta0.20
Dividend %- Quick Ratio- Sales past 5Y2.00% Gross Margin81.70% 52W Low103.80% ATR0.26
Employees10 Current Ratio12.80 Sales Q/Q0.00% Oper. Margin- RSI (14)61.16 Volatility9.77% 9.63%
OptionableNo Debt/Eq0.00 EPS Q/Q45.20% Profit Margin- Rel Volume0.54 Prev Close3.28
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume63.98K Price3.22
Recom- SMA2010.06% SMA5027.42% SMA200-16.55% Volume34,229 Change-1.83%
May-27-20 07:20AM  
May-19-20 06:47AM  
May-15-20 08:00AM  
Apr-24-20 08:35AM  
Apr-20-20 09:00AM  
Apr-02-20 10:33AM  
Mar-12-20 07:30AM  
Feb-13-20 04:10PM  
Jan-06-20 09:21AM  
Dec-12-19 04:30PM  
Dec-03-19 07:30AM  
Nov-05-19 07:30AM  
Oct-21-19 07:30AM  
Aug-29-19 08:30AM  
Aug-14-19 04:05PM  
Jul-25-19 07:30AM  
Jun-20-19 12:12PM  
08:26AM  
07:30AM  
07:30AM  
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the development and advancement of treatments for dermatological and gastrointestinal indications. Its lead product candidate is EB01, a non-steroidal anti-inflammatory molecule to treat chronic allergic contact dermatitis. Edesa Biotech, Inc. has a collaborative research project with the National Research Council of Canada to develop novel immunotherapies for vitiligo, as well as other indications; and Light Chain Bioscience for the development and commercialization of two Phase 2-ready biologic drug candidates for various therapeutic, prophylactic, and diagnostic applications. The company was founded in 2015 and is headquartered in Markham, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Brooks Michael JPresidentMay 27Buy3.002,5007,4994,327May 29 09:20 AM
Nijhawan PardeepChief Executive OfficerMay 26Buy2.983,0008,9392,124,024May 28 12:19 PM
Nijhawan PardeepChief Executive OfficerMar 17Buy1.875,0009,3732,121,024Mar 19 10:34 AM
Sistilli CarloDirectorJan 08Buy4.112,43610,0122,436Jan 10 02:13 PM
van der Velden PeterDirectorJan 08Buy3.20140,625450,0001,833,066Jan 10 02:13 PM
JOHNSON LORIN KDirectorJan 08Buy4.118,52435,0348,524Jan 10 02:11 PM
Brooks Michael JPresidentJan 08Buy4.111,8277,5091,827Jan 10 02:09 PM